Jan 10 (Reuters) - Gensight Biologics SA:
* GENSIGHT BIOLOGICS RECEIVES MHRA APPROVAL TO INITIATE PHASE I/II PIONEER CLINICAL TRIAL OF GS030 GENE THERAPY IN RETINITIS PIGMENTOSA 